Effects of neutral endopeptidase 24.11 inhibition on myocardial infarct size and ischemic preconditioning in rabbits

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 366, Issue 4, 2002, Pages 335-342

  Nakano, Atsushi ^a   Miura, Tetsuji ^a   Miki, Takayuki ^a   Nozawa, Yukinaga ^a   Ichikawa, Yoshihiko ^a   Ura, Nobuyuki ^a   Shimamoto, Kazuaki ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Bradykinin; Infarct size; Ischemic preconditioning; Neutral endopeptidase

Indexed keywords

ANGIOTENSIN I; BRADYKININ; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; ICATIBANT; MEMBRANE METALLOENDOPEPTIDASE; THIORPHAN;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG INFUSION; ENZYME ACTIVITY; ENZYME INHIBITION; HEART INFARCTION; HEART INFARCTION PREVENTION; HEART INFARCTION SIZE; HEART MUSCLE REPERFUSION; HEART PROTECTION; HEMODYNAMICS; HYPOTENSION; MALE; NONHUMAN; PRESSOR RESPONSE; RABBIT;

ANIMALS; BLOOD PRESSURE; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MALE; MYOCARDIAL INFARCTION; NEPRILYSIN; PROTEASE INHIBITORS; RABBITS; THIORPHAN;

EID: 0036380360     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00210-002-0600-8     Document Type: Article

References (41)

1. Anand-Srivastava MB, Trachte GJ (1993) Atrial natriuretic factor receptors and signal transduction mechanisms. Pharmacol Rev 45:455-497
2. Blais CJR, Drapeau G, Raymond P, Lamontagne D, Gervais N, Venneman I, Adam A (1997) Contribution of angiotensin-converting enzyme to the cardiac metabolism of bradykinin: an interspecies study. Am J Physiol 273:H2263-H2271
3. Burrell LM, Farina NK, Balding LC, Johnston CI (2000) Beneficial renal and cardiac effects of vasopeptidase inhibition with S21402 in heart failure. Hypertension 36:1105-1111
4. ATP channel. Annu Rev Physiol 62:79-109
5. Daniell HB, Carson RR, Ballard KD, Thomas GR, Privitera PJ (1984) Effects of captopril on limiting infarct size in conscious dogs. J Cardiovasc Pharmacol 6:1043-1047
6. Dragovic T, Minshall R, Jackman HL, Wang LX, Erdos EG (1996) Kininase II-type enzymes: their putative role in muscle energy metabolism. Diabetes 45 [Suppl]:S34-S37
7. Erdos EG, Skidgel RA (1989) Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones. FASEB J 3:145-151
8. Ferro CJ, Spratt JC, Haynes WG, Webb DJ (1998) Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo. Circulation 97:2323-2330
9. Goto M, Liu Y, Yang X-M, Ardell JL, Cohen MV, Downey JM (1995) Role of bradykinin in protection of ischemic preconditioning in rabbit hearts. Circ Res 77:611-621
10. Inserte J, Garcia-Dorado D, Agullo L, Paniagua A, Soler-Soler J (2000) Urodilatin limits acute reperfusion injury in the isolated rat heart. Cardiovasc Res 45:351-359
11. Itoya M, Miura T, Sakamoto J, Urabe K, Iimura O (1994) Nucleoside transport inhibitors enhance the infarct size-limiting effect of ischemic preconditioning. J Cardiovasc Pharmacol 24:846-852
12. Kasahara Y, Ashihara Y (1981) Colorimetry of angiotensin-1 converting enzyme activity in serum. Clin Chem 27:1922-1925
13. Kentsch M, Otter W, Drummer C, Notges A, Gerzer R, Muller-Esch G (1996) Neutral endopeptidase 24.11 inhibition may not exhibit beneficial haemodynamic effects in patients with congestive heart failure. Eur J Clin Pharmacol 51:269-272
14. Kokkonen JO, Kuoppala A, Saarinen J, Lindstedt KA, Kovanen PT (1999) Kallidin and bradykinin-degrading pathways in human heart: degradation of kallidin by aminopeptidase M-like activity and bradykinin by neutral endopeptidase. Circulation 99:1984-1990
15. Leesar MA, Stoddard MF, Manchikalapudi S, Bolli R (1999) Bradykinin-induced preconditioning in patients undergoing coronary angioplasty. J Am Coll Cardiol 34:639-650
16. Liang CS, Gavras H, Black J, Sherman LG, Hood WB Jr (1982) Renin-angiotensin system inhibition in acute myocardial infarction in dogs: effect on systemic hemodynamics, myocardial blood flow, segmental myocardial function and infarct size. Circulation 66:1249-1255
17. Maki T, Nasa Y, Yamaguchi F, Yoshida H, Mori M, Takada T, Horikawa E, Okano K, Takeo S (2001) Long-term treatment with neutral endopeptidase inhibitor improves cardiac function and reduces natriuretic peptides in rats with chronic heart failure. Cardiovasc Res 51:608-617
18. Margulies KB, Barclay PL, Burnett JC Jr (1995) The role of neutral endopeptidase in dogs with evolving congestive heart failure. Circulation 91:2036-2042
19. Marleau S, Ong H, Brochu M, Yamaguchi N, Lean AD, Souich PD (1990) Endogenous atrial natriuretic factor after endopeptidase 24.11 inhibition by thiorphan. Peptides 11:387-391
20. Miki T, Miura T, Shimamoto K, Urabe K, Sakamoto J, Iimura O (1993) Do angiotensin converting enzyme inhibitors limit myocardial infarct size? Clin Exp Pharmacol Physiol 20:429-434
21. 2 receptor activation. J Am Coll Cardiol 28:1616-1622
22. Miura T, Ogawa T, Iwamoto T, Shimamoto K, Iimura O (1992) Dipyridamole potentiates the myocardial infarct size-limiting effect of ischemic preconditioning. Circulation 86:979-985
23. 2 receptor activation in human heart. J Am Coll Cardiol 29:1599-1606
24. Northridge DB, Currie PF, Newby DE, McMurray JJ, Ford M, Boon NA, Dargie HJ (1999) Placebo-controlled comparison of candoxatril, an orally active neutral endopeptidase inhibitor, and captopril in patients with chronic heart failure. Eur J Heart Fail 1:67-72
25. Nozawa Y, Miura T, Tsuchida A, Kita H, Fukuma T, Shimamoto K (1999) Chronic treatment with an ACE inhibitor, temocapril, lowers the threshold for the infarct size-limiting effect of ischemic preconditioning. Cardiovasc Drugs Ther 13:151-157
26. O'Connor CM, Gattis WA, Gheorghiade M, Granger CB, Gilbert J, McKenny JM, Messineo FC, Burnett JC, Katz SD, Elkayam U, Kasper EK, Goldstein S, Cody RJ, Massie BM (1999) A randomized trial of ecadotril versus placebo in patients with mild to moderate heart failure: the U.S. ecadotril pilot safety study. Am Heart J 138:1140-1148
27. Raut R, Rouleau JL, Blais JRC, Gosselin H, Molinaro G, Sirois MG, Lepage Y, Crine P, Adam A (1999) Bradykinin metabolism in the postinfarcted rat heart: role of ACE and neutral endopeptidase 24.11. Am J Physiol 276:H1769-H1779
28. Roques BP, Noble F, Dauge V, Fournie-Zaluski MC, Beaumont A (1993) Neutral endopeptidase 24.11: structure, inhibition, an experimental and clinical pharmacology. Pharmacol Rev 45:87-118
29. Schriefer JA, Broudy EP, Hassen AH (1996) Endopeptidase inhibitors decrease myocardial ischemia/reperfusion injury in an in vivo rabbit model. J Pharmacol Exp Ther 278:1034-1039
30. Schultz JJ, Rose E, Yao Z, Gross GJ (1995) Evidence for involvement of opioid receptors in ischemic preconditioning in rat hearts. Am J Physiol 268:H2157-H2161
31. Schulz R, Post H, Vahlhaus C, Heusch G (1998) Ischemic preconditioning in pigs: a graded phenomenon: its relation to adenosine and bradykinin. Circulation 98:1022-1029
32. Schulz R, Cohen MV, Behrends M, Downey JM, Heusch G (2001) Signal transduction of ischemic preconditioning. Cardiovasc Res 52:181-198
33. Solter P, Sisson D, Thomas W, Goetze L (2000) Intrarenal effects of ecadotril during acute volume expansion in dogs with congestive heart failure. J Pharmacol Exp Ther 293:989-995
34. 2+ channel activity by human natriuretic peptide in rabbit heart cells. Br J Pharmacol 114:1076-1082
35. Wall TM, Sheehy R, Hartman JC (1994) Role of bradykinin in myocardial preconditioning. J Pharmacol Exp Ther 270:681-689
36. Wegner M, Hirth-Dietrich C, Stasch JP (1996) Role of neutral endopeptidase 24.11 in AV fistula rat model of heart failure. Cardiovasc Res 31:891-898
37. 1-receptor antagonism. Br J Pharmacol 131:138-144
38. Westheim AS, Bostrom P, Christensen CC, Parikka H, Rykke EO, Toivonen L (1999) Hemodynamic and neuroendocrine effects for candoxatril and furosemide in mild stable chronic heart failure. J Am Coll Cardiol 34:1794-1801
39. Willenbrock R, Scheuermann M, Hohnel K, Luft FC, Dietz R (1996) Acute and chronic neutral endopeptidase inhibition in rats with aortocaval shunt. Hypertension 27:1259-1266
40. Wirth K, Hock FJ, Albus U, Linz W, Alpermann HG, Anagnostopoulos H, Henke S, Breipohl G, Konig W, Knolle J, Schölkens BA (1991) Hoe140, a new potent and long acting bradykinin antagonist, in vivo studies. Br J Pharmacol 102:774-777
41. Yang X-P, Liu Y-H, Peterson E, Carretero OA (1997) Effect of neutral endopeptidase 24.11 inhibition on myocardial ischemia/reperfusion injury: the role of kinins. J Cardiovasc Pharmacol 29:250-256